Abstract
Pergolide is a dopamine agonist that improves Parkinson disease but is associated with dose-dependent sleepiness. This study evaluates the effect of a nighttime dose of 1 mg of pergolide on actigraphic measures of sleep using a randomized, double-blind, placebo-controlled study design. The pergolide group (n = 10) worsened in actigraphic measures of sleep efficiency and sleep fragmentation vs the placebo group (n = 12). Side effects were more frequent in the pergolide group.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Age Factors
-
Aged
-
Antiparkinson Agents / administration & dosage
-
Antiparkinson Agents / adverse effects
-
Brain / drug effects
-
Brain / metabolism
-
Brain / physiopathology
-
Circadian Rhythm / drug effects
-
Circadian Rhythm / physiology
-
Constipation / chemically induced
-
Dizziness / chemically induced
-
Dopamine Agonists / administration & dosage
-
Dopamine Agonists / adverse effects*
-
Double-Blind Method
-
Drug Administration Schedule
-
Drug Synergism
-
Drug Therapy, Combination
-
Female
-
Humans
-
Levodopa / administration & dosage
-
Male
-
Middle Aged
-
Nausea / chemically induced
-
Parkinson Disease / complications*
-
Parkinson Disease / drug therapy*
-
Parkinson Disease / physiopathology
-
Pergolide / administration & dosage
-
Pergolide / adverse effects*
-
Placebos
-
Sex Factors
-
Sleep / drug effects
-
Sleep / physiology
-
Sleep Wake Disorders / chemically induced
-
Sleep Wake Disorders / diagnosis
-
Sleep Wake Disorders / etiology*
-
Treatment Outcome
Substances
-
Antiparkinson Agents
-
Dopamine Agonists
-
Placebos
-
Pergolide
-
Levodopa